# Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

> **NCT00674141** · PHASE1 · WITHDRAWN · sponsor: **Hadassah Medical Organization** · enrollment: 10 (estimated)

## Conditions studied

- MS Patient With Relpasing Remitting Attacks

## Interventions

- **DRUG:** Dexamethasone soduim phosphate

## Key facts

- **NCT ID:** NCT00674141
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** was not approved by the ministry of health
- **Last updated:** 2010-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674141, "Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00674141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*